About the Authors
- Kerstin Höhne
-
Affiliations Division of Internal Medicine, Department of Pneumology, University Medical Centre, Freiburg, Germany, Faculty of Biology, University of Freiburg, Freiburg, Germany
- Stephan J. Schließmann
-
Affiliation Division of Internal Medicine, Department of Pneumology, University Medical Centre, Freiburg, Germany
- Andreas Kirschbaum
-
Affiliation Division of Surgery, Department of Thoracic Surgery, University Medical Centre, Freiburg, Germany
- Till Plönes
-
Affiliation Division of Surgery, Department of Thoracic Surgery, University Medical Centre, Freiburg, Germany
- Joachim Müller-Quernheim
-
Affiliation Division of Internal Medicine, Department of Pneumology, University Medical Centre, Freiburg, Germany
- Hermann Tenor
-
Affiliation Nycomed GmbH Global Discovery, Nycomed GmbH, Konstanz, Germany
- Gernot Zissel
-
* E-mail: gernot.zissel@uniklinik-freiburg.de
Affiliation Division of Internal Medicine, Department of Pneumology, University Medical Centre, Freiburg, Germany
Competing Interests
This study was supported by a research grant from Nycomed GmbH, Konstanz, Germany. HT is an employee of Nycomed GmbH. GZ is a PLoS ONE Editorial Board member. Roflumilast is the effective component of “Daxas” which is sold by Nycomed for COPD treatment to minimize exacerbations. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: KH JMQ HT GZ. Performed the experiments: KH HT. Analyzed the data: KH SJS GZ. Contributed reagents/materials/analysis tools: KH SJS AK TP. Wrote the paper: KH SJS GZ.